AstraZeneca’s FluMist approval for self-administration could increase flu vaccine uptake: GlobalData
According to GlobalData, the US vaccination rate for seasonal influenza during the 2023-2024 season was estimated to be 47%, and this rate is only expected to increase marginally over the coming years.
With FDA nod, AstraZeneca's FluMist becomes first self-administered flu vaccine
AstraZeneca has just scored big on the quest to make routine vaccinations less of a hassle. | The FDA signed off on AstraZeneca's influenza vaccine FluMist for self-administration by adults up to 49 years old and for administration by a parent or caregiver in kids between the ages of 2 and 17.
GlobalData on MSN3d
EMA CHMP recommends AstraZeneca’s Fasenra to treat EGPACommittee for Medicinal Products for Human Use (CHMP) has recommended approving AstraZeneca’s Fasenra (benralizumab) to treat ...
AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically ...
And on 20 September, the US FDA approved AstraZeneca’s FluMist influenza nasal spray vaccine for self-administration.
FluMist won't be available until next year, according to the website for FluMist, which is owned by AstraZeneca. Once ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback